

**Claims**

1. A pharmaceutical formulation for oral administration with extended release properties comprising an amount of gepirone hydrochloride, an  
5 amount of a cellulosic polymer matrix and an amount of microcrystalline cellulose characterised in that the amount the pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85 wt %, the amount of carbohydrate binder is from 7 to 10 wt % and the amount of gepirone hydrochloride is from 13 to 21 wt %.
- 10 2. The pharmaceutical formulation according to claim 1, characterised in that the cellulosic polymer matrix is a hydroxymethyl propylcellulose having a viscosity of 15,000 cps to 100,000 cps.
- 15 3. The pharmaceutical formulation according to claim 1, characterised in that the microcrystalline cellulose is Avicel pH 101.
4. A treatment for depression or a related central nervous system disorder with gepirone administered in a once-a-day oral formulation for  
20 extended release of gepirone, characterised in that the formulation is according to claim 1.